Cyclophosphamide rescue therapy for relapsed low-grade alimentary lymphoma after chlorambucil treatment in cats. Issue 10 (October 2021)

• Record Type: Journal Article
• Authors: Kim, Changseok; Wouda, Raelene M; Borrego, Juan; Chon, Esther
• Is Part Of: Journal of feline medicine and surgery. Volume 23:Issue 10(2021)
• Page Start: 976
• Page End: 986
• Publication Date: 2021-10
• Subjects: Cyclophosphamide -- lymphoma -- alimentary -- gastrointestinal -- GI -- relapsed -- recurrent -- rescue; Cats -- Diseases -- Periodicals; Cats -- Surgery -- Periodicals; 636.8089
• DOI: 10.1177/1098612X21996498
• Languages: English
• ISSNs: 1098-612X

Abstract

Objectives: The aims of this study were to evaluate the response, outcome and prognostic factors in cats with clinically presumed relapsed low-grade alimentary lymphoma (LGAL) receiving cyclophosphamide as a first-line rescue therapy after failing chlorambucil treatment. Methods: The medical records of 20 cats (from three institutions, between 2002 and 2017) treated with cyclophosphamide for relapsed LGAL after initial treatment with chlorambucil were retrospectively reviewed. Progression-free survival (PFS), overall survival time (OST) and the association of select variables with measures of outcome were assessed. Adverse events (AEs) were also described. Results: Eighteen cats (90%) achieved a complete clinical response (CR) for a median duration of 239 days. The median PFS was 215 days. The median OST was 1065 days. The only clinical factor associated with a longer PFS was achievement of a CR with cyclophosphamide treatment. Cyclophosphamide was associated with few and reversible constitutional, gastrointestinal and hematologic AEs. Conclusions and relevance: Cyclophosphamide appears to be a safe and effective first-rescue therapeutic option for cats with relapsed LGAL.